Skip to main content
Normal View

Medicinal Products Reimbursement

Dáil Éireann Debate, Tuesday - 15 January 2019

Tuesday, 15 January 2019

Questions (663)

Donnchadh Ó Laoghaire

Question:

663. Deputy Donnchadh Ó Laoghaire asked the Minister for Health if the application for reimbursement of Ocrevus for persons with relapsing MS and primary progressive MS has been discussed by the HSE drugs group; if so, the decisions that were made; if these drugs will be on the agenda for the next meeting of the HSE leadership team; when persons with MS who are eligible candidates for Ocrevus can expect to have access to same; and if he will make a statement on the matter. [54511/18]

View answer

Written answers

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.

Top
Share